Anzeige
Mehr »
Login
Donnerstag, 13.03.2025 Börsentäglich über 12.000 News von 691 internationalen Medien
Aktie des Tages: Die nächste Chance auf einen potentiellen Multi-Tenbagger
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JHKZ | ISIN: US6026701010 | Ticker-Symbol: N/A
1-Jahres-Chart
CTT PHARMACEUTICAL HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
CTT PHARMACEUTICAL HOLDINGS INC 5-Tage-Chart
ACCESS Newswire
389 Leser
Artikel bewerten:
(2)

CTT Pharmaceutical Holdings, Inc.: CTT Pharma Reduces Authorized Share Count

Finanznachrichten News

TAMPA, FL / ACCESS Newswire / February 3, 2025 / CTT Pharmaceuticals Holdings, Inc. (OTC:CTTH) is pleased to announce a reduction in its authorized share count by 150 million shares. CTT reduced the authorized share count from 300 million shares to 150 million shares. This change has already been filed with Delaware Division of Corporations. Furthermore, CTT's stock issuer has been notified and made the necessary corrections to reflect this change. This latest adjustment demonstrates CTT Pharma's ongoing commitment to optimizing its capital structure and delivering long-term value to shareholders. CTT is also in the process of gaining approval to uplist to the OTCQB and believes this decision benefits existing and future shareholders.

About CTT Pharmaceuticals Holdings, Inc.

CTT has patented technology in The United States, Europe, Canada and many additional countries to allow many actives on a dissolvable strip that include but are not limited to Nicotine, Vitamins, and Pharmaceuticals. CTT believes that there is a need for our technology in many industries, which includes a smoke-free nicotine strip that can be used as a smoking cessation product and deliver drugs that can help with pain management and anxiety. CTT Pharma incorporates micelle technology into its drug delivery. These strips would dissolve quickly, deliver low dose options and offer better bioavailability.

Investor Relations - 813-606-0060

SOURCE: CTT Pharmaceuticals Holdings, Inc.



View the original press release on ACCESS Newswire

© 2025 ACCESS Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.